Compare Amylx Pharmaceuticals Inc (AMLX) vs GraniteShares 2x Long COIN Daily ETF (CONL) Price & Performance

AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.

The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.

CONL (GraniteShares 2x Long COIN Daily ETF) trades at $4.065, down 0.61% on the day, with a bearish technical outlook as moving averages and key indicators signal selling pressure. The ETF has experienced significant volatility, losing 67% year-to-date according to 24/7 Wall Street (2026-06-06), reflecting the inherent risks of daily-reset leveraged strategies. Recent news highlights the challenges of timing leveraged ETF investments, with investors missing substantial returns due to poor trading timing.

The outlook remains challenging given the ETF's structure amplifies daily Coinbase volatility. While cryptocurrency trends may offer occasional upside, the daily reset mechanism creates compounding risks that have eroded value significantly. Investors should understand this is a tactical trading instrument, not a long-term investment vehicle, with high risk of capital erosion during volatile periods.